68 related articles for article (PubMed ID: 3298621)
21. Suppression of S-antigen-induced experimental autoimmune uveoretinitis in Lewis rats by oral administration with CGS-13080, a thromboxane synthetase inhibitor.
Li Q; Lopez JS; Caspi RR; Roberge FG; Nussenblatt RB; Kador PF; Chan CC
Exp Eye Res; 1993 Nov; 57(5):601-8. PubMed ID: 8282047
[TBL] [Abstract][Full Text] [Related]
22. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
23. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors.
Korbut R; Dembińska-Kieć A; Swies J; Zmuda A; Gryglewski RJ
Thromb Haemost; 1987 Oct; 58(3):827-30. PubMed ID: 3324381
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiological mechanisms of sudden death induced by platelet activating factor.
Lefer AM; Müller HF; Smith JB
Br J Pharmacol; 1984 Sep; 83(1):125-30. PubMed ID: 6435705
[TBL] [Abstract][Full Text] [Related]
25. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange.
Schermuly RT; Roehl A; Weissmann N; Ghofrani HA; Schudt C; Tenor H; Grimminger F; Seeger W; Walmrath D
J Pharmacol Exp Ther; 2000 Feb; 292(2):512-20. PubMed ID: 10640287
[TBL] [Abstract][Full Text] [Related]
26. Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death.
Kitzen JM; Lynch JJ; Uprichard AC; Venkatesh N; Lucchesi BR
Pharmacology; 1988; 37(3):171-86. PubMed ID: 3227051
[TBL] [Abstract][Full Text] [Related]
27. Interaction between thromboxane A2 and angiotensin II in postischemic renal vasoconstriction in dogs.
Abels BC; Branch RA; Sabra R
J Pharmacol Exp Ther; 1993 Mar; 264(3):1285-92. PubMed ID: 8450463
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of platelet activation by quinones isolated from Auxemma oncocalyx Taub.
Ferreira MA; Nunes OD; Fujimura AH; Pessoa OD; Lemos TL; Viana GS
Res Commun Mol Pathol Pharmacol; 1999; 106(1-2):97-107. PubMed ID: 11127812
[TBL] [Abstract][Full Text] [Related]
29. [Effects of neferine and its combination with taurine on platelet aggregation and experimental thrombosis in rats].
Huang HL; Rao MR
Yao Xue Xue Bao; 1995; 30(7):486-90. PubMed ID: 7484155
[TBL] [Abstract][Full Text] [Related]
30. Differential effect of CGS 13080, a thromboxane synthase inhibitor, in suppressing serum and urine immunoreactive thromboxane B2 in kidney transplant patients.
Foegh ML; Lim K; Douglas F; Turk J; Helfrich GB; Taher SA; Alijani MR
Transplant Proc; 1988 Feb; 20(1 Suppl 1):424-7. PubMed ID: 3279631
[No Abstract] [Full Text] [Related]
31. Selective thromboxane synthase inhibition does not increase in vivo synthesis of prostacyclin in healthy humans.
Vesterqvist O; Gréen K; Henriksson P; Rasmanis G; Edhag O
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():165-8. PubMed ID: 1825536
[No Abstract] [Full Text] [Related]
32. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors.
Levens NR; Ksander GM; Zimmerman MB; Mullane KM
Hypertension; 1989 Jan; 13(1):51-62. PubMed ID: 2910814
[TBL] [Abstract][Full Text] [Related]
33. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
Butler KD; Butler PA; Shand RA; Ambler J; Wallis RB
Thromb Res; 1987 Mar; 45(6):751-61. PubMed ID: 3109067
[TBL] [Abstract][Full Text] [Related]
34. [Effect of cicletanine on prostacyclin generation in vivo].
Bourgain RH; Deby C; Andries R
Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():33-6. PubMed ID: 2514665
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.
Lefer AM; Mentley R; Sun JZ
Circ Res; 1988 Sep; 63(3):621-7. PubMed ID: 3136950
[TBL] [Abstract][Full Text] [Related]
36. Effects of CI-930 on hemostasis, thrombosis, and AA-induced hemodynamic reaction.
Jiang YY; Fu CD; Liao LM; Huang TG; Chen XS; Long K
Zhongguo Yao Li Xue Bao; 1991 Jul; 12(4):331-5. PubMed ID: 1807082
[TBL] [Abstract][Full Text] [Related]
37. Effect of antithrombotic agents after carotid endarterectomy in rats.
Spallone A; Sasaki T; Kassell NF; Yamashita M
Neurosurgery; 1985 Jun; 16(6):780-5. PubMed ID: 3892356
[TBL] [Abstract][Full Text] [Related]
38. 1986: Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs. Updated in 1994.
DeAnda A; Miller DC
Ann Thorac Surg; 1994 Mar; 57(3):778-80. PubMed ID: 7511885
[No Abstract] [Full Text] [Related]
39. Lack of protective effect of thromboxane synthetase inhibitor (CGS-13080) on single dose radiated canine intestine.
Barter JF; Marlow D; Kamath RK; Harbert J; Torrisi JR; Barnes WA; Potkul RK; Newsome JT; Delgado G
Gynecol Oncol; 1991 Mar; 40(3):218-21. PubMed ID: 2013442
[TBL] [Abstract][Full Text] [Related]
40. Fetal and maternal response to intravenous infusion of a thromboxane synthetase inhibitor.
Cardin JP; Ross MG; Ervin MG; Schaffer AV; Douglas FL; Simke JP
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1345-9. PubMed ID: 2220946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
